What is Global Flu (Influenza) Vaccine Market?
The Global Flu (Influenza) Vaccine Market is a vast and dynamic sector that plays a crucial role in public health. It involves the production, distribution, and administration of vaccines that protect against the influenza virus, a contagious respiratory illness that can cause mild to severe illness and at times can lead to death. The market is driven by various factors such as the prevalence of influenza, advancements in vaccine technology, government initiatives for immunization, and the presence of a robust distribution network. However, it also faces challenges such as vaccine storage and handling issues, side effects associated with vaccines, and the high cost of vaccine development. The market is characterized by the presence of several key players who are engaged in research and development activities to introduce more effective and safer vaccines.
Split Influenza Vaccine, Pandemic Influenza Vaccine, Subunit Influenza Vaccine, Quadrivalent Influenza Vaccine in the Global Flu (Influenza) Vaccine Market:
The Global Flu (Influenza) Vaccine Market is segmented based on the type of vaccine. These include Split Influenza Vaccine, Pandemic Influenza Vaccine, Subunit Influenza Vaccine, and Quadrivalent Influenza Vaccine. The Split Influenza Vaccine is prepared by breaking down the virus into smaller parts, which are then used to produce the vaccine. This type of vaccine is commonly used due to its safety and efficacy. The Pandemic Influenza Vaccine is developed specifically for a pandemic strain of the virus. The Subunit Influenza Vaccine contains only the essential parts of the virus, reducing the risk of side effects. The Quadrivalent Influenza Vaccine protects against four different flu viruses; two influenza A viruses and two influenza B viruses. Each of these vaccines plays a vital role in preventing the spread of influenza and protecting public health.
For Children (6 months to 3 years), For Adults and Children over 3 years in the Global Flu (Influenza) Vaccine Market:
The Global Flu (Influenza) Vaccine Market also varies based on the age group of the recipients. The vaccines are used For Children (6 months to 3 years), and For Adults and Children over 3 years. For children aged 6 months to 3 years, the vaccine is crucial as their immune system is still developing, making them more susceptible to severe complications from influenza. For adults and children over 3 years, the vaccine helps to reduce the risk of flu-related complications, hospitalizations, and deaths. It's important to note that the dosage and administration of the vaccine may vary based on the age and health condition of the recipient.
Global Flu (Influenza) Vaccine Market Outlook:
To provide a snapshot of the Global Flu (Influenza) Vaccine Market, in 2022, the market was valued at US$ 5505 million. It is projected to reach a value of US$ 7088.2 million by 2029, growing at a Compound Annual Growth Rate (CAGR) of 3.6% during the forecast period from 2023 to 2029. The Quadrivalent Influenza Vaccine segment holds the largest share in the market, accounting for nearly 85% of the total market. This significant share can be attributed to the vaccine's ability to provide broader protection against the influenza virus.
| Report Metric | Details |
| Report Name | Flu (Influenza) Vaccine Market |
| Accounted market size in 2022 | US$ 5505 in million |
| Forecasted market size in 2029 | US$ 7088.2 million |
| CAGR | 3.6% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Hualan Bio, CCBIO, Aleph Biomedical, SANOFI, Adimmune, ZYAK, SINOVAC, Changsheng Biological, SIOBP, GSK, Aimei Hissen, Tianyuan Bio-pharma(Novartis), Simcere Vaxtec |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
